- Meta-analysis suggests platinum-based doublet therapy plus radiotherapy (RT) significantly prolongs survival in patients with locally advanced cervical cancer vs RT plus single-agent chemotherapy.
- Platinum-based doublet therapy group was associated with higher risk for toxicities.
Why this matters
- Concurrent chemoradiation is still the first-line treatment for locally advanced cervical cancer, but there is no standard chemotherapy regimen.
- Platinum-based doublet therapy should be considered in patients who are able to tolerate it.
- Meta-analysis of 7 randomized controlled trials including 1503 patients with locally advanced cervical cancer undergoing radiotherapy (RT) with concurrent platinum-based doublet or cisplatin monotherapy.
- Outcomes: OS, PFS, and safety.
- Funding: None.
- Concurrent RT with platinum-based doublet chemotherapy significantly improved OS and PFS vs RT with cisplatin monotherapy:
- OS: 7 studies; HR, 0.75 (P=.01).
- PFS: 7 studies; HR, 0.78 (P=.01).
- RT+doublet chemotherapy group showed higher risk for:
- vomiting (related ratio [RR], 3.19; P<.0001>
- thrombocytopenia (RR, 2.75; P=.004), and
- urinary system toxicity (RR, 4.58; P=.05).
- Only 2 phase 3 trials included.